Cytokinetics presents new aficamten data from ACACIA-HCM and FOREST-HCM at HCMS Scientific Sessions 2026

Cytokinetics presented new data on its drug candidate aficamten at the HCMS Scientific Sessions 2026, held with the American Heart Association Scientific Sessions. The presentations included two late-breaking oral abstracts with data from the ACACIA-HCM Phase 3 trial evaluating aficamten on cardiac structure and function in non-obstructive hypertrophic cardiomyopathy patients.

Detected & updated continuously · Source: Nebula